Belite Bio (BLTE) Cash & Equivalents (2021 - 2025)

Belite Bio's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $15.6 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 50.62% year-over-year to $15.6 million in Q4 2025; TTM through Dec 2025 was $15.6 million, a 50.62% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, down 50.62% from the prior year.
• Cash & Equivalents eased to $15.6 million in Q4 2025 per BLTE's latest filing, from $157.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $157.0 million in Q3 2025 and bottomed at $15.6 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $36.9 million (2022), against an average of $58.7 million.
• Across the five-year window, Cash & Equivalents surged 142.67% in 2022 and slumped 64.07% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $17.3 million in 2021, then surged by 142.67% to $42.1 million in 2022, then jumped by 109.45% to $88.2 million in 2023, then slumped by 64.07% to $31.7 million in 2024, then tumbled by 50.62% to $15.6 million in 2025.
• Per Business Quant, the three latest BLTE Cash & Equivalents figures stand at $15.6 million (Q4 2025), $157.0 million (Q3 2025), and $31.7 million (Q4 2024).